Detalles de la búsqueda
1.
Clinico-pathologic relationships with Ki67 and its change with short-term aromatase inhibitor treatment in primary ER + breast cancer: further results from the POETIC trial (CRUK/07/015).
Breast Cancer Res
; 25(1): 39, 2023 04 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37046348
2.
Relationship between ER expression by IHC or mRNA with Ki67 response to aromatase inhibition: a POETIC study.
Breast Cancer Res
; 24(1): 61, 2022 09 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36096872
3.
Estrogen-regulated feedback loop limits the efficacy of estrogen receptor-targeted breast cancer therapy.
Proc Natl Acad Sci U S A
; 115(31): 7869-7878, 2018 07 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-29987050
4.
Embryonic transcription factor SOX9 drives breast cancer endocrine resistance.
Proc Natl Acad Sci U S A
; 114(22): E4482-E4491, 2017 05 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-28507152
5.
Heterogeneity in global gene expression profiles between biopsy specimens taken peri-surgically from primary ER-positive breast carcinomas.
Breast Cancer Res
; 18(1): 39, 2016 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27036195
6.
Relationship of ZNF423 and CTSO with breast cancer risk in two randomised tamoxifen prevention trials.
Breast Cancer Res Treat
; 158(3): 591-6, 2016 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-27400912
7.
Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer.
Breast Cancer Res
; 12(5): R76, 2010.
Artículo
en Inglés
| MEDLINE | ID: mdl-20920193
8.
Assessment of the Spatial Heterogeneity of Breast Cancers: Associations Between Computed Tomography and Immunohistochemistry.
Biomark Cancer
; 11: 1179299X19851513, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31210736
9.
The Lineage Determining Factor GRHL2 Collaborates with FOXA1 to Establish a Targetable Pathway in Endocrine Therapy-Resistant Breast Cancer.
Cell Rep
; 29(4): 889-903.e10, 2019 10 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-31644911
10.
The farnesyltransferase inhibitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo.
Mol Cancer Ther
; 6(9): 2458-67, 2007 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-17876043
11.
Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer.
Clin Cancer Res
; 12(3 Pt 2): 1024s-1030s, 2006 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-16467120
12.
Immunohistochemical Phenotype of Breast Cancer during 25-Year Follow-up of the Royal Marsden Tamoxifen Prevention Trial.
Cancer Prev Res (Phila)
; 10(3): 171-176, 2017 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-28100469
13.
Impact of a Panel of 88 Single Nucleotide Polymorphisms on the Risk of Breast Cancer in High-Risk Women: Results From Two Randomized Tamoxifen Prevention Trials.
J Clin Oncol
; 35(7): 743-750, 2017 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-28029312
14.
Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase.
J Clin Oncol
; 23(11): 2469-76, 2005 Apr 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-15753463
15.
Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists.
J Clin Oncol
; 23(11): 2477-92, 2005 Apr 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-15767642
16.
Evaluation of Ki-67 proliferation and apoptotic index before, during and after neoadjuvant chemotherapy for primary breast cancer.
Breast Cancer Res
; 8(3): R31, 2006.
Artículo
en Inglés
| MEDLINE | ID: mdl-16790076
17.
Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival.
Clin Cancer Res
; 11(2 Pt 2): 951s-8s, 2005 Jan 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-15701892
18.
Comparison of the selective estrogen receptor modulator arzoxifene (LY353381) with tamoxifen on tumor growth and biomarker expression in an MCF-7 human breast cancer xenograft model.
Cancer Res
; 63(19): 6516-22, 2003 Oct 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-14559845
19.
Integration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancer.
Clin Cancer Res
; 9(1 Pt 2): 524S-32S, 2003 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-12538510
20.
Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039).
Clin Cancer Res
; 21(13): 2932-40, 2015 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-25398453